Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03507790 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Phase 2 study of Mild to Moderate Alzheimer's Disease, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT03507790 is a Phase 2 study of Mild to Moderate Alzheimer's Disease that has completed, run by Cognition Therapeutics. The registered enrollment target is 153 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT03507790, a Phase 2 study of Mild to Moderate Alzheimer's Disease, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CT1812
Study Locations (20)
Florida
- JEM Research Institute - Atlantis
- Charter Research - Lady Lake
- ClinCloud, LLC - Maitland
- Allied Biomedical Research Institute - Miami
- Compass Research LLC- Bioclinica Research - The Villages
- ClinCloud - Viera
Other
- Neuro Health Centrum ltd - Brno
- NeuropsychiatrieHK S.R.O - Hradec Králové
- A-Shine S.R.O - Pilsen
- Clintrial S.R.O - Prague
Victoria
- St Vincent's Hospital Sydney - Ivanhoe
- Alfred Health - Melbourne
- Melbourne Health - Parkville
Arizona
- 21st Century Neurology/ Xenoscience Inc. - Phoenix
- Imaging Endpoints - Scottsdale
Ohio
- The Ohio State University - Wexner - Columbus
- Neuro Behavirol Clinical Research C - North Canton
Connecticut
- Ki Health Partners, LLC dba New England Institute for Clinical Research - Stamford
North Carolina
- Alzheimer's Memory Center - Charlotte
Western Australia
- Australian Alzheimer's Research Foundation - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2024-05-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03507790
The ClinicalTrials.gov registry entry for NCT03507790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild to Moderate Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03507790 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Other, Victoria.
Frequently Asked Questions
What is clinical trial NCT03507790 about?
NCT03507790 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.". This is a multi-center, randomized, double-blind, placebo-controlled, parallel group 36 week multicenter Phase 2 study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease (AD).
What is the current status of trial NCT03507790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2018-10-10. Estimated completion is 2024-05-29.
What conditions does trial NCT03507790 study?
This clinical trial studies the following conditions: Mild to Moderate Alzheimer's Disease.
What interventions are being tested in trial NCT03507790?
The interventions under investigation include: Placebo (DRUG), CT1812 (DRUG).
Who is sponsoring clinical trial NCT03507790?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03507790 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild to Moderate Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.